A number of novel polyfluoro-substituted pyrazolopyrimidine compounds or salts are provided. The compounds are bruton tyrosine kinase (btk) inhibitors. The compounds have better kinase inhibition selectivity and pharmacokinetic properties. A preparation method for the compounds is also provided. Combination therapy is also provided which includes the compounds in combination with another target drug composition or another drug. optimized combination therapy has a cooperative effect, inhibiting the existence of a tumor better than a single target drug and causing certain tumors to disappear completely. optimized combined therapy treats tumor drug resistance and recurrence better than a single target drug and the treatment cycle is shorter. The present invention also relates to a combined compound and a pharmaceutical preparation wherein said combined compound acts as an active ingredient, said pharmaceutical preparation being safer at a lower dosage and having a cooperative effectiveness. Also provided is a method of use of the compounds and a preparation thereof for treating and inhibiting an autoimmune disease or disease, a heterogeneous autoimmune disease or disease, an inflammatory disease, a cancer or a disease.é fornecida uma série de novos compostos de pirazolopirimidina polifluoro-substituídos ou sais. os compostos são inibidores da tirosina quinase de bruton (btk). os compostos têm uma melhor seletividade de inibição de quinase e propriedades farmacocinéticas. também é fornecido um método de preparação para os compostos. também é fornecida uma terapia combinada que inclui os compostos em combinação com outra composição de fármaco alvo ou outro fármaco. a terapia combinada otimizada tem um efeito cooperativo, inibindo a existência de um tumor melhor do que um único fármaco alvo e faz com que determinados tumores desapareçam completamente. a tera-pia combinada otimizada trata a resistência a fármacos e recorrência de câncer de um tumor melhor do que um único f
